Ascendis to investigate new indications following EU approval

Ascendis Pharma is ready to sell its growth hormone for children in the EU after Thursday's approval from the European Commission, but more indications are on the drawing board.
Photo: Kevin Grønnemann / MedWatch
Photo: Kevin Grønnemann / MedWatch
by ANDREAS LØNSTRUP, translated by daniel pedersen

On Thursday, Danish biotech firm Ascendis Pharma could celebrate the EU Commission's formal approval of Lonapegsomatropin, previously dubbed Transcon hGH, which is a once-weekly injection for pediatric patients with growth hormone deficiency (GHD).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading